Clearside Biomedical Reports Revenue Growth but Continues to Face Net Losses in Q2 2025

Clearside Biomedical, Inc. reported its financial results for the second quarter of 2025, revealing a significant increase in license and other revenue, which rose to $492,000 from $90,000 in the same period last year. For the six months ending June 30, 2025, total revenue reached $2.8 million, a substantial increase from $320,000 in the prior year. Despite this revenue growth, the company continued to experience net losses, reporting a loss of $4.5 million for the quarter and $12.7 million for the first half of 2025, compared to losses of $7.6 million and $19.4 million, respectively, in the same periods of 2024.

Operating expenses for the second quarter decreased to $4.1 million from $7.7 million year-over-year, primarily due to reduced research and development costs, which fell to $1.6 million from $4.6 million. This decline was attributed to the completion of the ODYSSEY Phase 2b clinical trial for the CLS-AX program. General and administrative expenses also decreased, reflecting a reduction in employee-related costs. The company’s accumulated deficit increased to $368 million as of June 30, 2025, up from $355 million at the end of 2024.

In terms of strategic developments, Clearside announced plans in July 2025 to explore a range of strategic alternatives to enhance its SCS platform and drug development pipeline. This includes potential asset sales, partnerships, or mergers. As part of this strategic review, the company implemented a reduction in force, transitioning all employees to consulting roles, which is expected to incur approximately $2.6 million in severance costs in the third quarter of 2025. The company has paused all internal research and development programs during this evaluation period.

Operationally, Clearside's cash and cash equivalents decreased to $9.4 million as of June 30, 2025, down from $20 million at the end of 2024. The company reported net cash used in operating activities of $10.6 million for the first half of 2025, a slight improvement from $13.5 million in the same period of 2024. The company’s financing activities generated minimal cash flow, primarily from the sale of common stock under a controlled equity offering agreement.

Looking ahead, Clearside expressed substantial doubt regarding its ability to continue as a going concern, citing the need for additional financing to fund operations and the potential for bankruptcy if strategic alternatives do not materialize. The company emphasized that it does not expect to generate significant revenue until its product candidates receive regulatory approval and are commercialized. As such, the outlook remains uncertain, with the company focusing on securing necessary funding to sustain its operations and advance its product pipeline.